Use of a prenylation inhibitor as a novel antiviral agent.
J Virol
; 72(11): 9303-6, 1998 Nov.
Article
en En
| MEDLINE
| ID: mdl-9765479
No specific therapy exists for hepatitis delta virus (HDV), which can cause severe liver disease. Molecular genetic studies have implicated the prenylation site of large delta antigen as a critical determinant of HDV particle assembly. We have established a cell culture model which produces HDV-like particles, and we show that delta antigen prenylation can be pharmacologically inhibited by the prenylation inhibitor BZA-5B. Furthermore, BZA-5B specifically abolishes particle production in a dose-dependent manner. These results demonstrate that the use of such a prenylation inhibitor-based antiviral therapy may be feasible and identify a novel class of potential antiviral agents.
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Oligopéptidos
/
Benzodiazepinas
/
Virus de la Hepatitis Delta
/
Prenilación de Proteína
Límite:
Animals
Idioma:
En
Revista:
J Virol
Año:
1998
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos